Prevalence and control of dyslipidaemia among diabetic patients with microalbuminuria in a Chinese hospital

Diabetes and Vascular Disease Research

Volumn 10, Issue 2, 2013, Pages 169-178

  Wang, Shao Hua ^a   Wang, Lu ^b   Zhou, Yi ^a   Guo, Yi Jing ^a   Yuan, Yang ^a   Li, Feng Fei ^a   Huang, Yan ^a   Xia, Wen Qing ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

diabetes; diabetic nephropathy; Dyslipidaemia; microalbuminuria

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHINA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE;

AGED; AGED, 80 AND OVER; ALBUMINURIA; CHINA; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874028895     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112454756     Document Type: Article

References (49)

1. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ. 2004 ; 328: 1105-1108
2. Standards of medical care in diabetes - 2011. Diabetes Care. 2011 ; 34: S11 - S61
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497
4. Goldberg RB. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes. Am J Manag Care. 2000 ; 6: S682 - S691
5. Jenkins AJ, Velarde V, Klein RL, et al. Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes. 2000 ; 49: 2160-2169
6. Wheeler DC. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins. J Nephrol. 2001 ; 14: S70 - S75
7. Narita T, Kakey M, Ito S. Aggressive antihypertensive treatment and serum lipid lowering therapy are necessary to prevent deterioration of the renal function even in elderly type 2 diabetic patients with persistent albuminuria. Gerontology. 2002 ; 48: 302-308
8. Chaturvedi N, Fuller JH, Taskinen MR, et al. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care. 2001 ; 24: 2071-2077
9. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998 ; 158: 998-1004
10. Diabetic nephropathy (position statement). Diabetes Care. 2002 ; 25: S85 - S89
11. Remmuzi G, Schiepatti A, Ruggenenti P. Nephropathy in patients with type-2 diabetes. N Engl J Med. 2002 ; 346: 1145-1151
12. Nephropathy in diabetes (position statement). Diabetes Care. 2004 ; 27: S79 - S83
13. A desktop guide to type 2 diabetes. Diabet Med. 1999 ; 16: 416-730
14. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis. 2003 ; 42: 617-622
15. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med. 1988 ; 318: 1657-1666
16. Coonrod BA, Ellis D, Becker DJ, et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 1993 ; 16: 1376-1383
17. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997 ; 51: 1908-1919
18. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven year prospective study. Diabet Med. 1999 ; 16: 918-925
19. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10 year prospective observational study. Diabetes Care. 2002 ; 25: 859-864
20. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990 ; 39: 1116-1124
21. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?. Diabetes. 2000 ; 49: 1399-1408
22. Gall MA, Hougaard P, BorchJohnsen K, et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997 ; 314: 783-788
23. Shoji T, Emoto M, Kawagishi T, et al. Atherogenic lipoprotein changes in diabetic nephropathy. Atherosclerosis. 2001 ; 156: 425-433
24. Kim DM, Ahn CW, Park JS, et al. An implication of hypertriglyceridemia in the progression of diabetic nephropathy in metabolically obese, normal weight patients with type 2 diabetes mellitus in Korea. Diabetes Res Clin Pract. 2004 ; 66: S169 - S172
25. Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006 ; 55: 1832-1839
26. Smulders Y, Rakic M, Stehouwer C, et al. Determinants of progression of microalbuminuria in patients with NIDDM: a prospective study. Diabetes Care. 1997 ; 20: 999-1005
27. Molitch ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol. 2006 ; 1: 1090-1099
28. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis. 2011 ; 218: 13-18
29. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 2004 ; 18: 805-815
30. Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther. 2008 ; 6: 1319-1330
31. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001 ; 59: 260-269
32. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006 ; 145: 117-124
33. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006 ; 17: 2006-2016
34. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987 ; 28: 613-628
35. Golay A, Zech L, Shi MZ, et al. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab. 1987 ; 65: 512-518
36. Kasim SE, Tseng K, Jen KL, et al. Significance of hepatic triglyceride lipase activity in the regulation of serum high density lipoproteins in type II diabetes mellitus. J Clin Endocrinol Metab. 1987 ; 65: 183-187
37. Mormile A, Veglio M, Gruden G, et al. Physiological inhibitors of blood coagulation and prothrombin fragment F 1+2 in type 2 diabetic patients with normoalbuminuria and incipient nephropathy. Acta Diabetol. 1996 ; 33: 241-245
38. Sibley SD, Hokanson JE, Steffes MW, et al. Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care. 1999 ; 22: 1165-1170
39. Shao-Hua W, Zi-Lin S, Xiong-Zhong R, et al. Dyslipidaemia among diabetic patients with ischemic stroke in a Chinese hospital. Clin Med J. 2009 ; 122: 2567-2572
40. Cockerill GW, Rye KA, Gamble JR, et al. High density lipoproteins inhibit cytokine induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995 ; 15: 1987-1994
41. Nelson CL, Karschimkus CS, Dragicevic G, et al. Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant. 2005 ; 20: 2420-2426
42. Sun L, Halaihel N, Zhang W, et al. Role of sterol regulatory element binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002 ; 277: 18919-18927
43. Jerums G, Allen TJ, Tsalamandris C, et al. Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia. 1993 ; 36: 1037-1044
44. Tseng CH. Differential dyslipidemia associated with albuminuria in type 2 diabetic patients in Taiwan. Clin Biochem. 2009 ; 42: 1019-1024
45. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2002 ; 358: 2026-2033
46. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med. 2006 ; 259: 259-266
47. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet. 2004 ; 364: 937-952
48. BaoDe C, DaGan Y, Yu C, et al. The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China. Clin Chim Acta. 2010 ; 411: 705-709
49. Sahadevan M, Kasiske BL. Hyperlipidemia in kidney disease: causes and consequences. Curr Opin Nephrol Hypertens. 2002 ; 11: 323-329